Nanotop (Human Serum Albumin)

Human serum albumin functions as a natural colloid that increases plasma oncotic pressure. When administered intravenously, it draws water from the interstitial space into the bloodstream, expanding the circulating volume. This helps maintain blood pressure, improve tissue perfusion, and correct low serum albumin levels in acute fluid‑loss states.

The dose of Nanotop is individualized and set by the prescribing clinician. Dosing depends on the patient’s weight, the severity of volume loss, serum albumin concentration, and the clinical situation. Healthcare professionals calculate the required amount to achieve the desired plasma oncotic pressure and intravascular volume.

Safety data for Nanotop in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. The prescriber must evaluate the clinical need and consider alternative therapies if appropriate.

To order Nanotop, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Nanotop (human serum albumin) provides colloid‑based volume expansion, offering a higher oncotic effect than crystalloid solutions such as saline or lactated Ringer's. Compared with synthetic colloids, albumin is a natural protein with a well‑characterized safety profile. It is preferred when a sustained increase in plasma oncotic pressure is required, especially in hypoalbuminemic patients.

Nanotop must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required for infusion.

Nanotop is administered by intravenous infusion. The solution is typically diluted in compatible IV fluids and infused slowly under continuous monitoring of vital signs. Administration rates are adjusted based on the patient’s hemodynamic response and the clinical indication, following the prescriber’s instructions.

The most serious risks include anaphylactic reactions, which can be life‑threatening and require immediate emergency treatment, and volume overload leading to pulmonary edema or heart failure. Clinicians should monitor patients closely for signs of allergic response and for rapid changes in fluid balance during and after infusion.

Nanotop should be avoided in patients with known hypersensitivity to human serum albumin or any component of the formulation. It is also contraindicated in individuals with severe uncontrolled heart failure or pulmonary edema where additional volume expansion could worsen the condition. Clinical judgment is required for patients with renal impairment or active bleeding.